carmofur has been researched along with Adenocarcinoma, Basal Cell in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 7.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system." | 7.66 | Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma." | 7.66 | Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980) |
| "We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1." | 3.71 | Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 3.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "Experimental chemotherapy with 5-fluorouracil (5-FU; 60 mg/kg), 1-hexylcarbamoyl-5-fluorouracil (HCFU; 70 mg/kg), 3-(3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxym ethyl-5- fluorouracil (BOF-A2; 30 mg/kg) and UFT (20 mg/kg as tegafur with uracil at a molar ratio of 1:4) was performed using human gastric (H-111) and colon (Co-4) carcinoma strains in nude mice." | 3.68 | Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. ( Abe, O; Arisawa, Y; Fujita, S; Ishibiki, K; Josui, K; Kodaira, S; Kubota, T; Mabuchi, K; Suto, A; Yamamoto, T, 1991) |
| "The combined effects of X-ray irradiation and 5-FU derivatives (5-FU, tegafur, HCFU) treatment were investigated in mouse adenocarcinoma-755." | 3.67 | [Combined effects of radiation and 5-FU derivatives]. ( Dokiya, T; Hashimoto, S; Kunieda, E; Miyamoto, H; Shigematsu, N; Tominaga, J, 1986) |
| "The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system." | 3.66 | Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma." | 3.66 | Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980) |
| "Feasibility of utilizing human gastric cancers as first transplant generation xenografts in nude mice for determining tumor sensitivity to chemotherapeutic agents was demonstrated by applying subrenal capsule (SRC) assay." | 1.28 | Subrenal capsule assay using nude mice as a predictor of the response of the gastric cancer to chemotherapy. ( Akiyama, S; Ito, A; Ito, K; Kondo, K; Satta, T; Takagi, H; Watanabe, T; Yamauchi, M, 1991) |
| "For the diffuse invasive type of gastric cancer, the changes in the X-ray finding such as stiffness and poor elasticity of gastric wall and malignant relief were also taken into consideration for the judgement." | 1.26 | [Evaluation of the therapeutic effect of HCFU (1-hexylcarbamoyl-5-fluorouracil) on non-resectable stomach cancer]. ( Chin, F; Hirasawa, H; Isono, K; Kimura, M; Kouzu, T; Okuyama, K; Onoda, S; Ryu, M; Sato, H; Satoh, H; Tounosu, N; Yamamoto, Y, 1982) |
| "After confirming the presence of gastric cancer, 1-n-hexylcarbamoyl-5-fluorouracil (HCFU), a derivative of 5-fluorouracil, was given to the dogs orally as capsules at a daily dose of 5 or 10 mg/kg body weight." | 1.26 | Chemotherapeutic study on canine gastric cancer induced by N-ethyl-N'-nitro-N-nitrosoguanidine. ( Aoyagi, M; Hirashima, T; Hirota, T; Kawachi, T; Matsukura, N; Sugimura, T; Takasugi, T; Uchida, E; Ushio, K; Yoshida, S, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (44.44) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osterlund, P | 2 |
| Orpana, A | 1 |
| Elomaa, I | 2 |
| Repo, H | 1 |
| Joensuu, H | 2 |
| Sadahiro, S | 1 |
| Mitomi, T | 1 |
| Noto, T | 1 |
| Kumada, K | 1 |
| Hiki, Y | 1 |
| Yamakawa, T | 1 |
| Amano, T | 1 |
| Oki, S | 1 |
| Otani, Y | 1 |
| Oka, H | 1 |
| Takahashi, T | 1 |
| Takemiya, S | 1 |
| Nishiyama, K | 1 |
| Yamamura, T | 1 |
| Tsuchiya, S | 1 |
| Ogawa, N | 1 |
| Akazawa, S | 1 |
| Honda, T | 1 |
| Sampi, K | 1 |
| Nakagawa, T | 1 |
| Fujiki, T | 1 |
| Kanda, Y | 1 |
| Futatsuki, K | 1 |
| Izuno, O | 1 |
| Suda, Y | 1 |
| Sato, H | 1 |
| Satoh, H | 1 |
| Isono, K | 1 |
| Onoda, S | 1 |
| Okuyama, K | 1 |
| Tounosu, N | 1 |
| Yamamoto, Y | 1 |
| Kimura, M | 1 |
| Chin, F | 1 |
| Kouzu, T | 1 |
| Ryu, M | 1 |
| Hirasawa, H | 1 |
| Tokuzen, R | 1 |
| Iigo, M | 1 |
| Hoshi, A | 1 |
| Kuretani, K | 1 |
| Tsuruo, T | 1 |
| Iida, H | 1 |
| Naganuma, K | 1 |
| Tsukagoshi, S | 1 |
| Sakurai, Y | 1 |
| Matsukura, N | 1 |
| Aoyagi, M | 1 |
| Kawachi, T | 1 |
| Uchida, E | 1 |
| Yoshida, S | 1 |
| Hirashima, T | 1 |
| Takasugi, T | 1 |
| Ushio, K | 1 |
| Hirota, T | 1 |
| Sugimura, T | 1 |
| Ikeda, M | 1 |
| Teshima, K | 1 |
| Noda, K | 1 |
| Yamagata, S | 1 |
| Sugawa, T | 1 |
| Okamura, S | 1 |
| Kubo, H | 1 |
| Sugimoto, O | 1 |
| Nakajima, H | 1 |
| Yamabe, T | 1 |
| Matsuda, T | 1 |
| Mabuchi, K | 2 |
| Kitaoka, H | 1 |
| Hirata, N | 1 |
| Kitaoka, U | 1 |
| Sasaki, K | 1 |
| Takasaka, H | 1 |
| Kawasaki, H | 1 |
| Matsunaga, T | 1 |
| Nakagawa, N | 1 |
| Shibata, K | 1 |
| Yabana, T | 1 |
| Yasojima, T | 1 |
| Furuhata, T | 1 |
| Hata, F | 1 |
| Hirata, K | 1 |
| Virkkunen, P | 1 |
| Nagawa, H | 1 |
| Muto, T | 1 |
| Sunouchi, K | 1 |
| Higuchi, Y | 1 |
| Tsurita, G | 1 |
| Watanabe, T | 2 |
| Sawada, T | 1 |
| Kubota, T | 1 |
| Fujita, S | 1 |
| Kodaira, S | 1 |
| Yamamoto, T | 1 |
| Josui, K | 1 |
| Arisawa, Y | 1 |
| Suto, A | 1 |
| Ishibiki, K | 1 |
| Abe, O | 1 |
| Yamauchi, M | 1 |
| Satta, T | 1 |
| Ito, A | 1 |
| Kondo, K | 1 |
| Akiyama, S | 1 |
| Ito, K | 1 |
| Takagi, H | 1 |
| Suzuki, T | 1 |
| Koizumi, J | 1 |
| Uchida, K | 1 |
| Shiraishi, H | 1 |
| Hori, M | 1 |
| Miyamoto, H | 1 |
| Dokiya, T | 1 |
| Tominaga, J | 1 |
| Kunieda, E | 1 |
| Shigematsu, N | 1 |
| Hashimoto, S | 1 |
| Asakawa, H | 1 |
| Koyama, K | 1 |
| Otake, S | 1 |
| Otawa, H | 1 |
| Takashima, S | 1 |
| Kinami, Y | 1 |
| Kiriyama, M | 1 |
| Tomita, F | 1 |
| Ueno, K | 1 |
| Miyazaki, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemo-radiation for Preoperative Enlarged Lateral Nodes in Advanced Low Rectal Cancer: a Phase III Randomized Controlled Trial[NCT02614157] | 51 participants (Actual) | Interventional | 2016-05-31 | Terminated (stopped due to The enrollment was too low) | |||
| Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy of Lower Rectal Cancer With Suspected Local Lymph Node Metastasis[NCT03587480] | 250 participants (Anticipated) | Interventional | 2018-12-17 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for carmofur and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
[Long-term administration of carmofur as a post-operative adjuvant chemotherapy for cervical adenocarcinoma. Cervical Adenocarcinoma Cooperative Research Association].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; | 1994 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
15 other studies available for carmofur and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
[Combination chemotherapy of CIS-diamminedichloroplatinum (II) and fluoropyrimidine derivatives for advanced gastric cancer: a preliminary report].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1984 |
[Evaluation of the therapeutic effect of HCFU (1-hexylcarbamoyl-5-fluorouracil) on non-resectable stomach cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; F | 1982 |
Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Drug Administration Schedule; Female; Fluorouracil; | 1980 |
Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; In Vitro Techniques | 1980 |
Chemotherapeutic study on canine gastric cancer induced by N-ethyl-N'-nitro-N-nitrosoguanidine.
Topics: Adenocarcinoma; Animals; Dogs; Fluorouracil; Humans; Male; Methylnitronitrosoguanidine; Stomach Neop | 1980 |
[A case of multiple liver metastases showing good response by administration of carmofur alone in an aged patient with colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neopla | 1999 |
[Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis].
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Pr | 2000 |
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2001 |
Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Enzyme Activation; Flu | 1991 |
Subrenal capsule assay using nude mice as a predictor of the response of the gastric cancer to chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Fluorouracil; Huma | 1991 |
Carmofur-induced organic mental disorders.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Electroencephalography; Female; Fluorouracil; Follow-U | 1990 |
[Combined effects of radiation and 5-FU derivatives].
Topics: Adenocarcinoma; Animals; Cell Division; Fluorouracil; Male; Mice; Radiotherapy Dosage; Tegafur | 1986 |
[Evaluation of combined radiotherapy of gastric carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1985 |
[Distribution of 1-hexycarbamoyl-5-fluorouracil in rats and human patients, and clinical results in patients with colorectal cancer].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Humans; Mal | 1986 |